EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy

Colin S Tan,1,2 Wei Kiong Ngo,2 Jian Ping Chen,2 Nikolle W Tan,1,2 Tock Han Lim,1,2 on behalf of the EVEREST Study Group

ABSTRACT

Purpose To describe the imaging standards, grading protocol and baseline characteristics of polypoidal choroidal vasculopathy (PCV) from the EVEREST study.

Methods In a prospective, multicentre study, confocal scanning laser ophthalmoscopy indocyanine green angiography (ICGA) was performed using a standardised imaging protocol. All images were graded using standardised, calibrated equipment by fellowship-trained ophthalmologists at the Central Reading Center.

Results Sixty-one patients with PCV were included in the study. ICGA characteristics included: nodular appearance stereoscopically (56 eyes, 91.8%), hypofluorescent halo (42, 68.9%), abnormal vascular network (54, 88.5%) and pulsation of the polyps (4, 6.6%). Colour fundus photography revealed orange subretinal nodules (34, 55.7%) and massive submacular haemorrhage (8, 13.1%). The mean area of the PCV lesion was 3.11 mm² (range, 0.2–10.7 mm²). The vascular channels filled within 7.3–32.0 s (mean: 17.9 s) while the mean filling time for polyps was 21.9 s (range, 7.3–40.4 s). Patients with massive submacular haemorrhage were less likely to have abnormal vascular channels seen on ICGA (28.6% vs 83.3% for those without massive haemorrhage, p = 0.001).

Conclusions The imaging and grading protocols and baseline characteristics of a multicentre, randomised controlled trial of PCV are described in detail, and may serve as reference for future randomised, controlled trials on PCV.

Clinical trial number This work was supported by Novartis Pharma AG, Basel, Switzerland grant number NCT00874323 (clinicaltrials.gov).

INTRODUCTION

Polypoidal choroidal vasculopathy (PCV) manifests with a variety of clinical presentations, such as serous and/or haemorrhagic detachments of the retinal pigment epithelium (RPE), serous subretinal fluid mimicking central serous chorioretinopathy, or as quiescent orange-red subretinal nodules.1–4 In many cases, PCV is clinically indistinguishable from occult choroidal neovascularisation due to neovascular age-related macular degeneration (AMD) and indocyanine green angiography (ICGA) is required to distinguish the two conditions.4 6 7

The differentiation of PCV from AMD is clinically relevant because the treatment responses of two diseases differ.4 9 While AMD has been shown to respond well to antivascular endothelial growth factor monotherapy, studies such as the EVEREST study10 have demonstrated better rates of polyp closure and improvements in visual acuity among patients receiving combination therapy with photodynamic therapy and intravitreal ranibizumab.8 In addition, there are reports of patients with presumed AMD who responded poorly to prolonged treatment with antivascular endothelial growth factor monotherapy. ICGA performed subsequently confirmed the diagnosis of PCV and treatment with photodynamic therapy led to resolution of the lesions with improvements in visual acuity.9

The accurate diagnosis of PCV is essential to ensure appropriate treatment and to allow comparison among various studies on PCV treatment. Although the ICGA features of PCV have been described to various extents in the literature,4 7 8 11–14 there are significant differences in the interpretation of ICGA for the diagnosis of PCV. In addition, several clinical conditions may mimic the appearance of PCV on ICGA, hence the need to use consistent diagnostic features of PCV.

The imaging methods and diagnostic criteria were only briefly discussed in the first report of the EVEREST Study.10 This paper aims to provide further details and explain the rationale of the imaging standards and grading protocol, and to describe the baseline ICGA lesion characteristics of the patients.

METHODS

This study was approved by the respective institutional review boards of the study sites. Written, informed consent was obtained from all patients prior to enrolment in the study.

Imaging protocol

Fluorescein angiograms and ICGA were performed using a confocal scanning laser ophthalmoscope (Heidelberg Retinal Angiograph (HRA), HRA-C/ HRA2/HRA Spectralis, Heidelberg Engineering, Germany). When performing confocal scanning laser ophthalmoscope angiograms, the dose of indocyanine green (ICG) required is significantly lower compared with flash ICGA. ICG 10 mg in 2 mL using the accompanying aqueous diluent kit (Akorn, Pulsion or equivalent, as approved by the local health authority) was injected through the anterior cubital fossa vein over ≤5 s.

The standard angiographic field for all frames was 30° centred on the fovea, with a resolution of
The filling times were read from the timer of the viewing software. Vascular channel filling time was defined as the first time the ICG dye was visible within the abnormal vascular channels. Polyp filling time was defined as the time of first dye appearance within a polyp.

A best-fit circle was drawn around each polyp using the drawing tools on the Heidelberg Eye Explorer software (figure 3A). The diameter of each circle was used to calculate the area of each polyp. The total lesion area was determined using the freehand drawing tool. The grader drew an outline which encompassed all polyps identified and the area of the abnormal vascular channels (identified using dynamic ICGA), and the software returned the total area in mm². The circle drawing tool was then used to draw a best-fit circle around the total lesion area, the diameter of which was the greatest linear dimension (figure 3B).

Stereo-pair colour fundus photographs were viewed using the Visupac viewer V4.4.4 (Carl Zeiss Meditec, Dublin, California, USA) and the Screen-Vu stereoscope. The presence of orange subretinal nodules and massive submacular haemorrhage (defined as submacular haemorrhage ≥4 disc areas) was noted from the colour fundus photographs.

RESULTS
Of 95 cases submitted for screening, 61 were diagnosed with PCV. The mean age was 65 years (range, 46–84 years, SD ±9.2 years), with 41 men (67.2%) and 20 women (32.8%). All patients were of Asian ethnicity. In 32 patients, the right eye was involved (53.5%) whereas the left eye was involved in 29 patients (47.5%).

The frequency of ICGA characteristics were as follows: nodular appearance, 56 (91.8%); hypofluorescent halo around the nodule, 42 (68.9%); presence of abnormal vascular network, 54 (88.5%); and pulsation of the polyp(s) on dynamic ICGA, 4 (6.6%). Using colour fundus photography, 34 (55.7%) had orange subretinal nodules and 8 (13.1%) presented with massive submacular haemorrhage.

The characteristics of the polyps and BNV are summarised in table 1. The number of polyps ranged from 1 to 9, with a median of 4. The polyp configurations included solitary—16 (26.2%), ring—28 (45.9%), cluster—15 (24.6%) and mixed configurations—2 (3.3%). The mean total polyp area was 0.25 mm² (median 0.21 mm²; range, 0.025–2.11 mm²; SD ±0.28 mm²). The area of the PCV lesion (comprising polyps and associated vascular channels) ranged from 0.2 mm² to 10.7 mm², with a mean of 3.11 mm² and a median of 2.28 mm².

Of the cases with associated vascular channels, 46 (75.4%) had a distinct BNV, whereas 8 (13.1%) were classified as interconnecting channels, as described above. The vascular channels (either BNV or interconnecting channels) filled within 7.3–32.0 s, with a mean of 17.9 s (median: 17.6 s) while the mean filling time for the polyps was 21.9 s (median: 22.0 s; range, 7.3–40.4 s, SD±8.1 s).

The patient manifested with a variety of clinical presentations, including serous subretinal fluid (28 (45.9%)), serosanguinous (23 (37.7%)), haemorrhagic (2 (3.3%)) and massive submacular haemorrhage (8 (13.1%)). Patients with massive submacular haemorrhage were less likely to have abnormal vascular channels on ICGA (37.5% vs 83.0% for those without massive haemorrhage, p=0.001). A higher percentage of patients with pulsation of the polyp on dynamic ICGA presented with haemorrhage of any size, 1 of 4 (25.0%) compared with 9 of 57 (15.8%) for those without pulsation, but the difference was not statistically significant (p=0.63). The frequency of
haemorrhagic presentations did not differ between those with orange subretinal nodules (5 patients, 14.7%) and those without nodules (5 patients, 18.5%).

**DISCUSSION**

In this paper, we have described the ICGA imaging standards, grading methods and diagnostic criteria used in the EVEREST Study, the first multicentre randomised controlled trial of PCV treatment. The baseline ICGA and colour fundus photograph characteristics of patients with PCV are also described. These methods may provide the reference for standardised imaging and grading protocols for PCV in future multicentre studies.

The relevance of the diagnostic criteria can be seen from the results of this paper. While earlier studies on PCV used a variety of clinical and ICGA features to diagnose PCV and differentiate it from neovascular AMD, these features were highly variable between studies and the characteristic appearance of a polyp was often not well-defined. In many papers, the polyps have been described as ‘polypoidal choroidal vascular dilatations’, ‘focal vascular dilations’, or ‘polypoidal lesions’. These terms, however, may mean different things and be interpreted differently by various clinicians. Therefore, it is imperative to use standardised criteria that are easy to apply across different studies in order to ensure that the results of these studies are comparable. In this study, three parameters were
used to describe a typical polyp using ICGA—nodular hyperfluorescence on stereoscopic ICGA (91.8%), hypofluorescent halo around the nodule (68.9%) and pulsation during dynamic ICGA (6.6%). We believe that stereo-pair ICGA images are essential in the diagnosis of PCV, as it allows the determination of nodularity (the most common diagnostic feature) and the depth of the lesions, which helps to differentiate vascular polyps from retinal lesions such as macular oedema, large microaneurysms and retinal angiomatous proliferation. This was of particular importance because spectral domain optical coherence tomography (SD-OCT) was not widely available in 2008 when this trial was underway. In future studies, SD-OCT may play an important role in determining the depth and shape of the PCV lesion.

Dynamic ICGA is an essential component of PCV diagnosis, as it allows identification of two of the six diagnostic criteria. The exact boundaries of abnormal vascular channels of the PCV lesion are best visualised in the early phase of the angiogram (within 30 s) and may not be seen as clearly after 1 min due to complete filling of the normal choroidal vessels. In addition, the presence of pulsation cannot be detected without the use of dynamic ICGA.

The abnormal vascular channels began to fill within 7.3–32 s from injection. Therefore, the use of dynamic ICGA for the first 30 s is sufficient to detect these vessels. In all cases, the polyps started to fill within 40.4 s from injection, with a mean of 21.9 s, which corresponds to the original description of early, intense focal hyperfluorescence on ICGA.12 Therefore, the use of either the 1-min or 3-min stereo-pair ICGA images should be adequate to assess the presence, location and extent of polyps and a later stereo-pair at ≥10 min may not be necessary. True late-onset focal hyperfluorescences (appearing after 6 min) are more likely to be focal ICG staining of unhealthy RPE or choroidal vascular knuckle showing through focal RPE atrophy (window defect). In both cases, stereo viewing would help to differentiate them.

In this series, 33 of 61 cases (54.1%) presented with subretinal haemorrhage. This highlights the importance of haemorrhage as diagnostic criteria for PCV as has previously been described.13 16 19–23 Ahuja et al17 reported that 85% of patients with haemorrhagic and exudative detachments had evidence of PCV on ICGA.

In several earlier papers, the presence of orange subretinal nodules was used to diagnose PCV17 19–21 24 25 This clinical feature was seen in 55.7% of cases in this study, thus highlighting that not all cases of PCV manifest with characteristic nodules and the need for ICGA to identify the PCV lesion.

The strengths of this study include the use of standardised imaging protocols and equipment on all cases of PCV. The diagnosis of PCV was made by applying stringent diagnostic criteria by expert graders from the Central Reading Center. The main limitation is the lack of data from OCT, which can potentially be used as one of the diagnostic criteria. In future studies, SD-OCT can play an invaluable role in identifying features which are characteristic of PCV and confirming the location of the hyperfluorescent nodule.

In conclusion, we have described the standardised imaging protocols, grading methods and diagnostic criteria used to diagnose PCV and highlighted important features in a prospective series of patients with PCV. It is hoped that these detailed techniques, and the baseline characteristics described, can be useful to clinical practice and future randomised controlled trials on PCV.

Table 1 Characteristics of polypoidal choroidal vasculopathy (PCV) lesion based on grading of indocyanine green angiography

<table>
<thead>
<tr>
<th></th>
<th>Mean (±SD)</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyps</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of polyps</td>
<td>4.1 (2.0)</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Diameter of smallest polyp within a single eye (mm)</td>
<td>0.19 (0.1)</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Diameter of largest polyp within a single eye (mm)</td>
<td>0.35 (0.2)</td>
<td>0.15</td>
<td>1.45</td>
</tr>
<tr>
<td>Total polyp area (mm²)</td>
<td>0.25 (2.0)</td>
<td>0.025</td>
<td>2.1</td>
</tr>
<tr>
<td>BVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVN area (mm²)</td>
<td>2.87 (2.5)</td>
<td>0.07</td>
<td>10.52</td>
</tr>
<tr>
<td>Percentage of total area accounted for by BVN (%)</td>
<td>85.5 (15.4)</td>
<td>28.0</td>
<td>98.8</td>
</tr>
<tr>
<td>Total PCV lesion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total lesion area (mm²)</td>
<td>3.1 (2.6)</td>
<td>0.2</td>
<td>10.7</td>
</tr>
<tr>
<td>Greatest linear diameter (mm)</td>
<td>2.5 (1.2)</td>
<td>0.7</td>
<td>5.1</td>
</tr>
</tbody>
</table>

BVN, branching vascular network.

Figure 3 Grading diagrams from the Central Reading Center. (A) Grading diagram illustrating the location of each polyp, with the diameter of each polyp shown by the figures in green. (B) Grading diagram illustrating the outline of the entire polypoidal choroidal vasculopathy (PCV) lesion (green), with a best-fit circle (yellow) used to calculate the greatest linear dimension (GLD). The area of the PCV lesion and the GLD are shown.
REFERENCES

Appendix 1. Fluorescein and indocyanine green angiography imaging sequence.

**Dynamic capture** (video angiography) for 30 seconds after the first appearance of the dye in the retinal (fluorescein angiography) or choroidal circulation (indocyanine green angiography).

**Still-frame 30-degree stereo pair images using automated real time setting** as follows:

1 min – 1 min 59 sec: 1 stereo pair of study eye

2 min – 2 min 59 sec: 1 stereo pair of fellow eye

3 min – 3 min 59 sec: 1 stereo pair of study eye

4 min – 4 min 59 sec: 1 stereo pair of fellow eye

5 min – 5 min 59 sec: 1 stereo pair of study eye

10min- 10min 59sec: 1 stereo pair of study eye

11min- 11min 59sec: 1 stereo pair of fellow eye

20min- 20min 59sec: 1 stereo pair of study eye

21min- 21min 59sec: 1 stereo pair of fellow eye